A Cornucopia of siRNA- and RNAi-based Therapeutics in Development Show Promise Researchers from academia and industry will present the latest developments in the application of interference RNA (RNAi) ...
RNA is a fundamental molecule of life that plays diverse structural, functional, and regulatory roles in all organisms and pathogenic viruses. In recent years, the discovery of new classes of RNA ...
RNA interference (RNAi) is an ancient genetic regulatory mechanism that modern-day scientists are trying to harness. Since its discovery more than 10 years ago, RNAi R&D has run the gamut from ...
– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – “We are excited to advance ALN-KHK to the clinic as our first RNAi therapeutic ...
Nicholas Dreisbach (left) is a Senior Associate Scientist in the RNA team at ElevateBio (MA, USA), where he deploys his skills as an expert in capillary gel electrophoresis (CGE) technologies. His ...
Maravai LifeSciences’ MRVI business, TriLink BioTechnologies, recently partnered with Johns Hopkins University to significantly enhance research in RNA therapeutics. This collaboration aims to ...
INDIANAPOLIS – (August 6, 2024) – Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, in partnership with Illumina, a leader in DNA sequencing and array-based ...
Unlocking Precision: The BD PAXgene ® Blood RNA tubes, as part of the Cell and Biomarker Preservation portfolio for research tubes, are an essential component of the PAXgene ® Blood RNA System. This ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback